ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
1-Year Return
4.95%
This Quarter Return
+12.73%
1 Year Return
+4.95%
3 Year Return
+16.8%
5 Year Return
+58.39%
10 Year Return
–
AUM
$225M
AUM Growth
-$5.82M
(-2.5%)
Cap. Flow
-$29.5M
Cap. Flow
% of AUM
-13.11%
Top 10 Holdings %
Top 10 Hldgs %
45.19%
Holding
92
New
27
Increased
21
Reduced
24
Closed
19
Top Buys
| 1 |
Sanofi
SNY
|
$5.95M |
| 2 |
WMGI
Wright Medical Group Inc
WMGI
|
$5.77M |
| 3 |
TVTY
Tivity Health, Inc. Common Stock
TVTY
|
$4.85M |
| 4 |
Bristol-Myers Squibb
BMY
|
$4.84M |
| 5 |
RCM
R1 RCM Inc. Common Stock
RCM
|
$4.75M |
Top Sells
| 1 |
Abbott
ABT
|
$13M |
| 2 |
Merck
MRK
|
$12.6M |
| 3 |
Johnson & Johnson
JNJ
|
$7.76M |
| 4 |
Universal Health Services
UHS
|
$7.16M |
| 5 |
AGN
Allergan plc
AGN
|
$6.96M |
Sector Composition
| 1 | Healthcare | 92.74% |
| 2 | Industrials | 2.11% |
| 3 | Financials | 2.08% |
| 4 | Technology | 0.89% |
| 5 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Fate Therapeutics
FATE
$112M
| $3.33M | 1.48% |
204,333
+121,761
| +147% | +$1.98M |
|
27
Iovance Biotherapeutics
IOVA
$796M
| $2.72M | 1.21% |
+242,169
| New | +$2.72M |
|
28
Boston Scientific
BSX
$159B
| $2.71M | 1.21% |
70,407
-2,434
| -3% | -$93.7K |
|
29
Icon
ICLR
$13.7B
| $2.48M | 1.1% |
+16,099
| New | +$2.48M |
|
30
Danaher
DHR
$143B
| $2.17M | 0.96% |
+22,502
| New | +$2.17M |
|
31
Quest Diagnostics
DGX
$20.1B
| $2.12M | 0.94% |
+19,673
| New | +$2.12M |
|
32
Ocular Therapeutix
OCUL
$2.21B
| $2.08M | 0.92% |
302,153
+159,378
| +112% | +$1.1M |
|
|
IIN
33
DELISTED
IntriCon Corporation
IIN
| $2M | 0.89% |
+35,494
| New | +$2M |
|
|
HRC
34
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
| $1.88M | 0.83% |
19,865
-23,012
| -54% | -$2.17M |
|
35
UnitedHealth
UNH
$281B
| $1.84M | 0.82% |
6,922
-9,945
| -59% | -$2.65M |
|
|
ARRY
36
DELISTED
Array Biopharma Inc
ARRY
| $1.71M | 0.76% |
112,700
+31,284
| +38% | +$476K |
|
|
NVRO
37
DELISTED
NEVRO CORP.
NVRO
| $1.38M | 0.61% |
24,171
+14,075
| +139% | +$802K |
|
38
Sarepta Therapeutics
SRPT
$1.93B
| $1.37M | 0.61% |
8,456
+1,742
| +26% | +$281K |
|
|
NXTM
39
DELISTED
NxStage Medical Inc.
NXTM
| $1.3M | 0.58% |
+46,513
| New | +$1.3M |
|
40
Viking Therapeutics
VKTX
$2.98B
| $1.25M | 0.56% |
71,977
+11,478
| +19% | +$200K |
|
41
Agilent Technologies
A
$36.4B
| $1.22M | 0.54% |
17,286
-12,125
| -41% | -$855K |
|
42
Puma Biotechnology
PBYI
$257M
| $1.15M | 0.51% |
25,081
-15,707
| -39% | -$720K |
|
|
MDRX
43
DELISTED
Veradigm Inc. Common Stock
MDRX
| $1.09M | 0.48% |
+76,494
| New | +$1.09M |
|
44
Axogen
AXGN
$709M
| $1.07M | 0.48% |
+29,074
| New | +$1.07M |
|
45
Adverum Biotechnologies
ADVM
$66.5M
| $1.02M | 0.45% |
+16,884
| New | +$1.02M |
|
46
Pediatrix Medical
MD
$1.48B
| $978K | 0.44% |
20,959
+11,517
| +122% | +$537K |
|
47
Aldeyra Therapeutics
ALDX
$332M
| $966K | 0.43% |
+70,000
| New | +$966K |
|
48
Sangamo Therapeutics
SGMO
$160M
| $924K | 0.41% |
+54,523
| New | +$924K |
|
49
Amicus Therapeutics
FOLD
$2.47B
| $856K | 0.38% |
70,768
+16,264
| +30% | +$197K |
|
50
MacroGenics
MGNX
$123M
| $846K | 0.38% |
+39,456
| New | +$846K |
|